Precision Medicine World
Conference – Silicon Valley
Visit Q2 Solutions Booth #23, meet our Experts and attend our Session on January 25 on Clinical Trials in Immunotherapy
About This EventView presentation and video of Q2 Solutions’ “Clinical Trials in Immunotherapy” Session at PMWC 2017.
Attend our session on Wednesday, January 25, 2017 at 11:30 to 12:30 PM in Track 2
Session Title: Clinical Trials in Immunotherapy
Session Synopsis: Undeniably, cancer immunotherapy is one of the most promising areas in cancer research. New clinical trial approaches are under way to advance immune therapies for cancer. We will hear from industry and medical representatives about their novel and innovative immunotherapy programs which have the goal to expedite treatment of cancer.
- Patrice Hugo, PhD, CSO Q2 Solutions
- Jonathan D. Cheng, M.D, Executive Director, Oncology Clinical Research, Merck Research Laboratories
- Samir Klheif, M.D, Director of GRU Cancer Center, Augusta University
- Jim Novatny, PhD; Group Director, Pharmacodiagnostics, Bristol-Myers Squib
Chief Scientific Officer
Patrice Hugo, Ph.D. is chief scientific officer of Q2 Solutions, a Quintiles Quest Joint Venture. Dr. Hugo leads the organization’s global scientific strategy and implementation, developing and accelerating strategies to help improve human health through innovation that transforms science and data into actionable medical insights.
Dr. Hugo brings more than 25 years of senior scientific leadership experience with extensive management expertise in laboratory operations applied to diagnostics, therapeutic targets and clinical trials. Most recently, Dr. Hugo was Associate Vice President and Chief Scientist at Laboratory Corporation of America (LabCorp). He has held several other senior leadership positions at companies including LabCorp, Clearstone Central Laboratories, Caprion and PROCREA BioSciences. A noted industry expert, Dr. Hugo has more than 75 scientific publications in internationally renowned journals. He also is active in a number of industry organizations, including his role on the Board of Directors for the non-for-profit Personalized Medicine Partnership for Cancer in Quebec, Warnex offering analytical and bioanalytical services and his role as a Steering Committee Member for the Biomarker Factory.
Dr. Hugo obtained his Ph.D. at McGill University and completed five years of post- doctoral fellowship at the Walter Elisa Hall Institute in Australia, and Howard Hughes Medical Institute in Denver, Colorado.